We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation.
- Authors
Plummer, Ruth; Lorigan, Paul; Steven, Neil; Scott, Lucy; Middleton, Mark R; Wilson, Richard H; Mulligan, Evan; Curtin, Nicola; Wang, Diane; Dewji, Raz; Abbattista, Antonello; Gallo, Jorge; Calvert, Hilary
- Abstract
poly(ADP ribose) polymerase inhibition has been shown to potentiate the cytotoxicity of DNA damaging agents. A phase I study of rucaparib and temozolomide showed that full-dose temozolomide could be given during PARP inhibition. We report the results of a phase II study of intravenous rucaparib 12 mg/m(2) and oral temozolomide 200 mg/m(2) on days 1-5 every 28 days in patients with advanced metastatic melanoma.
- Publication
Cancer chemotherapy and pharmacology, 2013, Vol 71, Issue 5, p1191
- ISSN
1432-0843
- Publication type
Journal Article
- DOI
10.1007/s00280-013-2113-1